1. Home
  2. PDS vs DSGN Comparison

PDS vs DSGN Comparison

Compare PDS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precision Drilling Corporation

PDS

Precision Drilling Corporation

HOLD

Current Price

$96.68

Market Cap

1.3B

Sector

N/A

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$11.07

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDS
DSGN
Founded
1951
2017
Country
Canada
United States
Employees
5245
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
819.6M
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
PDS
DSGN
Price
$96.68
$11.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$122.33
$15.25
AVG Volume (30 Days)
95.1K
1.1M
Earning Date
04-29-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.66
N/A
Revenue Next Year
$2.31
N/A
P/E Ratio
$884.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$41.95
$3.33
52 Week High
$103.80
$17.25

Technical Indicators

Market Signals
Indicator
PDS
DSGN
Relative Strength Index (RSI) 53.93 40.09
Support Level $83.72 $9.25
Resistance Level $103.13 $13.54
Average True Range (ATR) 3.05 1.32
MACD 0.41 -0.52
Stochastic Oscillator 59.73 16.83

Price Performance

Historical Comparison
PDS
DSGN

About PDS Precision Drilling Corporation

Precision Drilling Corp is a provider of contract drilling, completion, and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. The company operates through two industry segments: Contract Drilling Services, which generates maximum revenue and includes drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale, and repair of drilling equipment; and Completion and Production Services, which includes service rigs, oilfield equipment rental, and camp services. The company generates the majority of its revenue from the United States.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: